Clinical trials: sponsored by The Netherlands Cancer Institute
Small Cell Lung Cancer, Brain Metastases, Adult
Tarlatamab for SCLC Brain Metastases
A single arm phase II study evaluating intracranial efficacy of tarlatamab in patients with asymptomatic active brain metastases from small cell lung cancer (SCLC).
- Trial name
- T-BRAIN (NCT07402343)
- Testing
- Tarlatamab
- Where
- 4 sites in Netherlands
- Volunteers
- 35 people
- Sponsor
- Maastricht University Medical Center
Peritoneal Metastases From Gastric Cancer
INTERACT Stomach-II
This is a phase II study conducted in three hospitals in the Netherlands (Erasmus MC in Rotterdam, Catharina Hospital in Eindhoven, and the Netherlands Cancer Institute in Amsterdam). A total of 55 patients will take part.
- Trial name
- NCT07133490
- Testing
- intraperitoneal chemotherapy
- Where
- 3 sites in Netherlands
- Volunteers
- 55 people
- Sponsor
- Erasmus Medical Center
Lung Cancer (NSCLC), HER2 Expression
Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer
The investigators investigate whether PET imaging with ⁸⁹Zr-trastuzumab can reliably demonstrate the extent of tracer accumulation in tumors of patients with HER2-mutated or HER2-overexpressing non-small cell lung cancer (NSCLC).
- Conditions
- Lung Cancer (NSCLC), HER2 Expression, HER2 Gene Mutation
- Trial name
- NCT07436858
- Testing
- PET imaging with ⁸⁹Zr-trastuzumab, Blood sampling for pharmacokinetics
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer Detection, Breast Cancer
Screening and the Future of Enhanced MRI for Early Breast Cancer Detection
This study aims to recruit women aged 45 years in the Netherlands to participate in a one-time breast MRI screening examination and to evaluate their motivation for participation as well as the impact of screening on their…
- Conditions
- Breast Cancer Detection, Breast Cancer, Screening Strategy
- Trial name
- SAFE-MRI (NCT07878377)
- Testing
- Breast MRI Screening, Questionnaires
- Volunteers
- 2,628 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Lung Cancer
ARtificial Intelligence for Gross Tumour vOlume Segmentation
Identifying the outline of a Gross Tumour Volume (GTV) in lung cancer is an essential step in radiation treatment. Clinical research, such as radiomics and image-based prognostication, requires the GTV to be pre-defined on…
- Trial name
- ARGOS (NCT05775068)
- Testing
- Radiotherapy
- Where
- Netherlands
- Volunteers
- 2,000 people
- Sponsor
- Maastricht Radiation Oncology
Breast Cancer
TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer
This prospective, national, multi-centre study will include patients with stage III triple-negative breast cancer (TNBC) who are planned to start with standard (neo)adjuvant systemic treatment.
- Trial name
- TAO (NCT06931769)
- Where
- 9 sites in Netherlands
- Volunteers
- 100 people
- Sponsor
- The Netherlands Cancer Institute
Non Small Cell Lung Cancer, Immunotherapy
RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung Cancer
Traditionally, chemotherapy and/or immunotherapy are combined with surgery or radiotherapy to cure patients with lung cancer. However, some patients treated with immunotherapy appear to be cured before surgery or radiotherapy.
- Trial name
- RADICAL-IO (NCT07808138)
- Testing
- Cemiplimab 350 mg IV
- Where
- 2 sites in Netherlands
- Volunteers
- 30 people
- Sponsor
- The Netherlands Cancer Institute
Rectal Cancer
Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)
In this study, patients with resectable rectal cancer will receive radiotherapy, followed by neoadjuvant bevacizumab and atezolizumab
- Trial name
- TARZAN (NCT04017455)
- Testing
- Atezolizumab, Bevacizumab
- Where
- Netherlands
- Volunteers
- 38 people
- Sponsor
- The Netherlands Cancer Institute
Colon Carcinoma
Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer
In this exploratory study, patients with stage 1-3 adenocarcinoma of the colon with no signs of distant metastases will be treated with short-term immunotherapy + novel IO combinations (i.e.
- Trial name
- NICHE (NCT03026140)
- Testing
- Nivolumab, Ipilimumab, Celecoxib 200mg
- Where
- 6 sites in Netherlands
- Volunteers
- 353 people
- Sponsor
- The Netherlands Cancer Institute
Stomach Cancer, Gastro Esophageal Junction Cancer
Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)
In this explorative study, patients with resectabel cancer of the stomach or stomach-oesophagealjunction cancer will receive neoadjuvant treatment.
- Trial name
- PANDA (NCT03448835)
- Testing
- Atezolizumab, Capecitabine, Oxaliplatin
- Where
- 2 sites in Netherlands
- Volunteers
- 20 people
- Sponsor
- The Netherlands Cancer Institute
Soft Tissue Sarcomas
Short Course Of Preoperative Radiotherapy in Head and Neck-, Trunk- and Extremity Soft Tissue Sarcomas
Currently, soft tissue sarcomas (STS) are preoperatively irradiated in a conventionally fractionated regimen of 25 x 2 Gy in five weeks.
- Trial name
- SCOPES (NCT04425967)
- Testing
- pre-operative radiotherapy
- Where
- 4 sites in Netherlands
- Volunteers
- 168 people
- Sponsor
- The Netherlands Cancer Institute
Prostate Cancer
A Pilot Study of Dose dE-eScalaTion IN prostATe radIOtherapy usiNg the MRL
Trial design: A single centre phase II non-randomised study Trial population: Men with intermediate risk localised prostate cancer Recruitment target: 20 patients in total Trial objectives: Primary To develop a 5 fraction…
- Trial name
- DESTINATION (NCT06284304)
- Testing
- De-escalated radiotherapy
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- The Netherlands Cancer Institute
Prostate Cancer
Standard Moderately Hypofractionated RT vs. Ultra-hypofractionated Focal Lesion Ablative Microboost in Prostate Cancer
EBRT is one of the standard treatment options for patients with localized PCA. Based on the outcome of randomized trials, moderately hypofractionated RT(19-25 fractions of 2.5-3.4Gy) is considered equivalent to conventional…
- Trial name
- NCT05705921
- Testing
- Radiotherapy standard, Radiotherapy Hypo-FLAME
- Where
- Netherlands
- Volunteers
- 484 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer
Preoperative Accelerated Partial Breast Irradiation in Patients With Locally Recurrent or Second Primary Breast Cancer
This study evaluates the acute toxicity and feasibility of repeat breast conserving therapy with preoperative accelerated partial breast re-irradiation (PAPBI) in female patients aged 51 years or older with ipsilateral recurrent…
- Trial name
- PAPBI-3 (NCT06362616)
- Testing
- Preoperative accelerated partial breast irradiation, Breast conserving surgery, Sentinel node procedure
- Where
- Netherlands
- Volunteers
- 31 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer Invasive, Metastatic Cancer
COntinue the SaMe Systemic Therapy After Local Ablative Therapy for Oligo Progression in Metastatic Breast Cancer - the COSMO Study
Patients with oligoprogression of metastatic breast cancer during palliative treatment that is amenable to local therapy will be included.
- Conditions
- Breast Cancer Invasive, Metastatic Cancer, Oligoprogressive
- Trial name
- COSMO (NCT05301881)
- Testing
- Surgery, Radiotherapy, Radiofrequent ablation
- Where
- 7 sites in Netherlands
- Volunteers
- 56 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer
DiEtary Mimicry by Glucocorticoid Modulation Evaluation in ER+ Metastatic Breast Cancer Treatment: Efficacy and Response (DEMETER Trial)
This is a single centre, open label, phase II clinical study consisting of two parts, each consisting of a different dose of the same intervention to investigate the efficacy of dexamethasone as an adjunct to endocrine therapy in…
- Trial name
- DEMETER (NCT07786051)
- Testing
- Dexamethasone (Oral)
- Volunteers
- 80 people
- Sponsor
- The Netherlands Cancer Institute
Non-Small Cell Lung Carcinoma, Advanced Non-Small Cell Squamous Lung Cancer
Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT
Activity of patritumab deruxtecan (U3-1402; HER3-DXd) has been shown in a phase I/II study in patients with HER3 expressing breast cancer as well as in a phase I study in patients with EGFR TKI refractory EGFR mutation positive…
- Conditions
- Non-Small Cell Lung Carcinoma, Advanced Non-Small Cell Squamous Lung Cancer, EGFR Gene Mutation
- Trial name
- NCT06222489
- Testing
- 89Zr-Patritumab deruxtecan
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- The Netherlands Cancer Institute
Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases From Melanoma
Novel Ga68-PSMA PET/CT-tracer to Differentiate Between Radiation Necrosis and Tumor Progression in Brain Metastases
This study aims to evaluate the diagnostic potential of 68-Gallium PSMA-PET/CT in stereotactic irradiated brain metastases from non-small cell lung cancer, melanoma and breast cancer.
- Conditions
- Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases From Melanoma, Brain Metastases From Breast Cancer
- Trial name
- NCT07511933
- Testing
- 86-Gallium PSMA PET/CT
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- The Netherlands Cancer Institute
Penile Cancer, Melanoma
Validation of ICG-99mTc-nanoscan as Hybrid Tracer for Sentinel Node Biopsy
99mTc-nanocolloid, the world wide used hybrid tracer for dynamic sentinel node biopsy, has recently been replaced with 99mTc-nanoscan.
- Conditions
- Penile Cancer, Melanoma, Oral Cancer
- Trial name
- NANOSCAN (NCT06666634)
- Testing
- Sentinel node biopsy with either ICG-99mTc-nanoscan or 99mTc-nanoscan
- Where
- Netherlands
- Volunteers
- 29 people
- Sponsor
- The Netherlands Cancer Institute
Urologic Neoplasms, Urogenital Neoplasms
Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab
This is a non-blinded phase 2 trial in Stage II-IIIa urothelial cancer randomizing pre-operative nivolumab with or without relatlimab to assess whether bladder preservation after dual immunotherapy would be a viable treatment…
- Conditions
- Urologic Neoplasms, Urogenital Neoplasms, Neoplasms by Site, Neoplasms
- Trial name
- TURANDORELA (NCT06237920)
- Testing
- Nivolumab, Relatlimab
- Where
- 9 sites in Netherlands
- Volunteers
- 90 people
- Sponsor
- The Netherlands Cancer Institute